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httpcense.Abstract Background: Chronic Obstructive Pulmonary Disease (COPD) is a major cause of
chronic morbidity and mortality worldwide. It is the ﬁfth leading cause of death worldwide. The
spectrum of cardiovascular complications associated with COPD is clearly broad, right ventricular
(RV) dysfunction and pulmonary vascular disease are common in COPD and progress with time. In
RV failure, cardiac Troponins (cTn) are suspected to be elevated secondary to RV ischemia or
micro infarction.
Objective: To evaluate the prognostic value of cardiac Troponin I level in acute exacerbated
chronic obstructive pulmonary diseases (AECOPD) and its impact on the hospital outcome in those
patients.
Patients and methods: This study was performed on 60 patients with AECOPD, admitted at
Chest Department and respiratory ICU; Zagazig University hospital. All patients were subjected
to: thorough history taking, clinical examination, electrocardiography and echocardiography, arte-
rial blood gas (ABG) analysis, measure forced vital capacity (FVC) and forced expiratory volume in
ﬁrst second (FEV1), serum assay of cTnI level which is considered ve if <0.01 ng/ml and +ve if
P0.01 ng/ml.
Results: cTnI was positive in 42 AECOPD patients. cTnI positivity was more prominent among
patients with very severe exacerbation of COPD and in those with past history of LTOT, MV, ICU
admission. Also, cTnI positivity was more in patients admitted to ICU rather than those managed48293330.
m (R. El-Ghamry).
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550 A.R.I. Youssef et al.in the ward and among patients who needed MV rather than who did not need it and in patients
who failed weaned rather that who succeeded weaned. P-pulmonate, Rt. ventricular strain, high
pulmonary artery pressure, hypoxemia and hypercapnia showed a great effect upon cTnI positivity.
The duration of hospitalization was longer among cTnI +ve patients than cTnI ve ones, Tropinin
cutoff value for the prediction of death was >0.055 ng/ml with Sensitivity = 75%, Speciﬁc-
ity = 68%.
Conclusion: Positive cTnI in AECOPD patients may suggest exacerbation severity and the
occurrence of pulmonary hypertension and right ventricular dysfunction. Positive cTnI is consid-
ered as good prognostic marker for the possibility of a need for MV and a longer duration of hos-
pitalization. MV may further elevate cTnI in AECOPD patients and with possible weaning failure.
Negative cTnI and cTnI 6 0.055 lg/L can be considered predictors of survival in AECOPD
patients.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a major
cause of chronic morbidity and mortality worldwide. It is the
ﬁfth leading cause of death worldwide [1].
Exacerbation of COPD is an event in the natural course of
the disease characterized by a change in the patient’s baseline
dyspnea, cough and/or sputum beyond day-to-day variability
sufﬁcient to warrant a change in management. Acute exacerba-
tions of COPD (AECOPD) account for large amounts of the
morbidity and mortality attributed to COPD [2].
In patients hospitalized for acute exacerbation of COPD
cardiovascular risk factors and cardiac co-morbidity are com-
mon. Cardiac dysfunction may trigger acute exacerbation in
up to 25% of these patients, whereas acute respiratory failure
itself may lead to right or left ventricular failure (LV) [3].
The spectrum of cardiovascular complications associated
with COPD is clearly broad. Right ventricular (RV) dysfunc-
tion and pulmonary vascular disease are common in COPD
and progress with time. Other cardiac diseases found fre-
quently in patients with COPD, including coronary artery dis-
ease (CAD) and arrhythmias, present a unique challenge for
clinician as the combination of both pulmonary and cardiac
disease appears to be additive with regard to morbidity and
mortality [4].
The cardiovascular alterations are extremely complex. Dur-
ing an episode of acute exacerbation, the increased work and
oxygen cost of breathing, the increase in the left ventricular
afterload related to the more negative intrathoracic pressure,
the worsening of pulmonary hypertension, and the presence
of hypoxemia and hypercapnia may all contribute to the devel-
opment of cardiac injury [3].
So identiﬁcation of patients with cardiac injury may inﬂu-
ence the treatment and outcome. Identiﬁcation of cardiac dys-
function during acute COPD exacerbation remains difﬁcult
because of the non speciﬁc nature of clinical signs [5].
Therefore there is a need for a ‘‘biomarker’’ not only to
provide conﬁrmation of exacerbation but also to predict the
severity of such events [6].
Cardiac Troponin I (cTnI) is a speciﬁc marker for cardiac
injury. It is a component of the contractile proteins present
in all muscles. The amino acid sequence of cTnI contains a sec-
tion that is unique to cardiac muscle. The cTnI assay measures
these cardio-speciﬁc components to provide a highly speciﬁc
marker for cardiac muscle cell injury. It has no cross reactivitywith the two skeletal muscle isoforms. CTnI is a highly sensi-
tive and long-lasting marker of cardiac injury [7,8].
This work was carried out to evaluate the prognostic value
of Troponin I level in acute exacerbated chronic obstructive
pulmonary diseases (AECOPD) and its impact on the hospital
outcome in those patients.Patients and methods
The study included 60 patients with AECOPD who were
admitted at R ICU and Chest Department, Zagazig University
Hospitals. They were 39 males and 21 females, with an age
range from 35–73 years and its mean 58.22 ± 8.37 years.
They were divided according to their management into:
Thirty-ﬁve AECOPD patients requiring mechanical
ventilation.
Twenty-ﬁve A ECOPD patients non-mechanically venti-
lated either admitted in ward or RICU.
 Acute exacerbation of chronic obstructive pulmonary dis-
ease (AECOPD) was diagnosed on the basis of the patient’s
medical history, symptoms (increased dyspnea, increased
cough and sputum with change of color, wheezing and chest
tightness), physical examination and arterial blood gases
(ABGs) according to Global Initiative for chronic obstructive
Lung Disease (GOLD) guidelines [1].
 Respiratory failure was deﬁned as a PaO2 < 60 mm Hg
and/or SaO2 < 90% with or without PaCo2 > 50 mm Hg in
arterial blood gas measurements made while breathing room
air at sea level (GOLD, 1)
 Patients were mechanically ventilated by Servo-i and Puri-
tan Bennett 7200 and were on synchronized intermittent man-
datory ventilation (SIMV) plus pressure support ventilation.
Exclusion criteria [9].
Patients were excluded from the study if they had concomitant
severe diseases, such as: ischemic heart disease, previous myo-
cardial infarction, heart trauma, aortic valve disease and
hypertrophic obstructive cardiomyopathy with signiﬁcant left
ventricular hypertrophy, hypertension (malignant HTN), post-
operative noncardiac surgery patients, renal impairment,
hypothyroidism and hyperthyrodism.
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On admission, the following were carried out for all patients:
(1) Full medical history from the patient (if possible) or his
relatives including smoking status, number of previous
episodes [exacerbation (s)/hospitalization(s)], history of
previous intubation and/or ventilatory support, prior
evidence of cor-pulmonale with or without congestive
heart failure, co- morbidities and drug therapy, or long
term O2 therapy (LTOT).
(2) Full clinical examination (General & local chest
examination).
(3) Assessment of exacerbation severity according to
(Anthonisen et al. [10] and GOLD [1]).
(4) Plain chest and heart X-ray (postero-anterior or antero-
posterior) according to circumstances.
(5) Arterial blood gases analysis by means of a blood gas
analyzer.
(6) Electrocardiography (ECG): It was done to assess the
changes in P wave, cardiac axis deviations and other
parameters for the detection of pulmonary hypertension,
presence of ischemia or other diseases (Piazza and Gold-
haber) [11].
(7) Spirometric ventilatory pulmonary function test. Mea-
surement of FEV1 FEV1/FVC for assessment of severity
of the disease using a computerized pulmonary function
device (Sensor Medicus 2450 computerized pulmonary
function apparatus) as soon as the patient’s clinical con-
dition allowed testing and before discharge from the
hospital.
(8) C.T. pulmonary angiography was done to patients who
were suspected to have pulmonary embolism.
(9) Echocardiography (ECHO): echocardiographic exami-
nation is performed by echocardiographists (PHILPS
V3) M-mode and two-dimensional and Doppler imaging
were obtained using commercially available instruments
operating at 2.0–3.5 MHz. Performed in standard and
parasternal views. Echocardiographists were blinded to
Troponin I levels.
(10) Other laboratory investigations including (complete
blood count, liver and, kidney function tests, CRP,
serum electrolytes (Na, K) and sputum examination
(gram stain and ZN).
(11) Cardiac Troponin1 measurement for all cases within
24 h of admission, assay by VIDAS Troponin I Ultra
(TNIU) (by BioMerieux, France), use of VIDAS instru-
ments for the determination of human cardiac Troponin
I in human serum using ELFA (Enzyme-Linked Fluo-
rescent Assay) technique by one step immunoassay
sandwich method with a ﬁnal ﬂuorescent detection [12].
The analytical detection limit, deﬁned as the smallest concen-
tration of cTnI which is signiﬁcantly different from zero concen-
tration with a probability of 95%, is 0.01 ng/ml detectable,
serum cTnI levelsP0.01 ng/ml are considered to be elevated.
Statistical analysis
Data were entered, checked and analyzed by SPSS for Win-
dows version 14.0. Data were summarized using: the arithme-tic mean ( X), the standard deviation (SD), Chi-Square (v2) test,
Student t-test 5-Mann–Whitney test. Descriminative diagnos-
tic values including Sensitivity, Speciﬁcity and receiver operat-
ing characteristic (ROC) Curve were assessed by Medical tests.
For all the above mentioned statistical tests were done, the
threshold of signiﬁcance is ﬁxed at 5% level (P-value). P-value
of >0.05 indicates non-signiﬁcant results. P value of <0.05
indicates signiﬁcant results.Results
The study was conducted on 60 patients with AECOPD they
were 39 males, 21 females with an age range of 35–73, 35 pa-
tients (58.3%) who required mechanical ventilation and 25
(41.7%) non mechanically ventilated. Cardiac Troponin, was
considered ve if <0.01 ng/ml, and +ve if P0.01 ng/ml.
In this study of cTnI +ve in 42 patients and cTnI ve in 12
patients, all baseline characteristics and clinical data of pa-
tients with AECOPD and its relation and effect to cardiac Tro-
ponin I level are summarized in Table 1, that shows non
statistical signiﬁcant difference in cTnI level in relation to
(age, sex, smoking habits and causes of exacerbation P
> 0.05), with a statistical signiﬁcant difference as regards the
severity of exacerbation, and those with a past history of
LTOT, ICU admission and mechanical ventilation,
(P< 0.05).
Table 2 shows that there was a signiﬁcant positive correla-
tion with PCO2, mPAP, duration of hospitalization also there
was a signiﬁcant inverse correlation between Tropinin level
and PO2, and SO2.
Table 3 shows that there were a signiﬁcant difference in
Troponin elevation as regards sinus tachycardia and P-pulmo-
nale, mPAP, right ventricular strain, left ventricular dysfunc-
tion and TR but a non signiﬁcant difference as regards AF
among the studied AECOPD patients.
Table 4 shows a signiﬁcant difference in Troponin level in
relation to Place of admission, need for MV and Outcome
(P< 0.05) as cTnI positivity was more prominent among pa-
tients who were admitted to the ICU (83%) rather than who
managed in the ward (17%), who were ventilated (97%) vs.
thosewhodid not needMV (3%), and in non Survival compared
with Survival as all dead patients were +ve cTnI, (n= 12).
Table 5 shows that there was a signiﬁcant statistical differ-
ence in the median of cTnI between patients who succeeded
(0.08) vs. those patients who failed (0.2).
Table 6 and theROCcurve show the following: The troponin
optimal cutoff value for the prediction of death was >0.055
ng/ml, area under the curve = 0.735, Sensitivity = 75%,
Speciﬁcity = 68%.Discussion
In patients hospitalized for acute exacerbation of COPD dis-
ease cardiovascular risk factors and cardiac co-morbidity are
common. Cardiac dysfunction may trigger acute exacerbation
in up to 25% of these patients, whereas acute respiratory fail-
ure itself may lead to right or left ventricular failure (LV) [3].
So the identiﬁcation of cardiac dysfunction during AE-
COPD remains difﬁcult because of the non-speciﬁc nature of
clinical signs [5].
Table 1 Baseline characteristics and clinical data of patients with AECOPD and its relation to cardiac Troponin I level (ng/ml).
Parameter cTnI < 0.01 (n= 18) cTnIP 0.01 (n= 42) P-value
Age (mean ± SD) 60.7 ± 10.2 58 ± 7.7 >0.05
Sex
Males (n: 39) 9 (50%) 30 (71.4%) >0.05
Females (n: 21) 9 (50%) 12 (28.6%)
Smoking
None (n: 23) 9 (50%) 14 (33.3%) >0.05
Ex- (n: 3) 0 (0%) 3 (7.1%)
Current smoker (n: 14) 9 (50.0%) 25 (59.6%)
Causes of exacerbation
Infection (n: 40) 15 (83.3%) 25 (59.5%) >0.05
PE (n: 10) 1 (5.6%) 9 (21.4%)
Unknown (n: 10) 2 (11.1%) 8 (19.1%)
Severity of exacerbation
Mild (n: 11) 8 (44.4%) 3 (7.1%) <0.05
Moderate (n: 14) 8 (44.4%) 6 (14.3%)
Severe (n: 35) 2 (11.2%) 33 (78.6%)
Past history of
LTOT (n: 19) 2 (11.1%) 17 (40.5%) <0.05
ICU admission (n: 21) 2 (11.1%) 19 (45.2%) <0.05
MV (n: 8) 0 (0%) 8 (19%) <0.05
Table 2 Correlation between Troponin level and (ABG
parameters, mPAP, duration of hospitalization) among studied
AECOPD patients.
Parameters R P
pH 0.18 >0.05
PCO2 0.49 <0.01
PO2 0.52 <0.001
SO2 0.42 <0.05
HCO3 0.11 >0.05
mPAP 0.54 <0.001
Duration of hospitalization 0.39 <0.05
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provide conﬁrmation of exacerbation but also to predict the
severity of such events [6].
Cardiac Troponin I (cTnI) is a speciﬁc marker for cardiac
injury. It is a component of the contractile proteins present
in all muscles. The amino acid sequence of cTnI contains a sec-
tion that is unique to cardiac muscle. The cTnI assay measures
these cardio-speciﬁc components to provide a highly speciﬁc
marker for cardiac muscle cell injury. It has no cross reactivity
with the two skeletal muscle isoforms. CTnI is a highly sensi-
tive and long-lasting marker of cardiac injury [7,8].
This work was carried out to evaluate the prognostic value
of Troponin I level in acute exacerbated chronic obstructive
pulmonary diseases (AECOPD) and its impact on the hospital
outcome in those patients.
The VIDAS Troponin I Ultra method that was used in this
study provides an excellent tool to aid in the early diagnosis of
myocardial injury, with very high clinical sensitivity. CTnI is
considered +ve if P0.01 ng/ml and ve if <0.01 ng/ml [12].
In the present study, cTnI was elevated (above 0.01 ng/ml)
in 70% of AECOPD patients, the mean age of patient with+ve cTnI was (58 ± 7.7) years and the mean age of patient
with ve cTnI was (60 ± 10.2) years with no signiﬁcant differ-
ence (Table 1). This is in agreement with Baillard et al. [3] who
found no signiﬁcant difference between +ve and ve cTnI
patients as regards age in their study.
In contrary, Harvey and Hancox [13] reported a signiﬁcant
difference in the mean age of +ve cTnI patients vs ve cTnI
patients.
As regards smoking habit there was no signiﬁcant statistical
difference in cTnI elevation among non smokers and smokers
(Table 1). This is in agreement with Baillard et al. [3] and Deveci
et al. [14] who excluded the effect of smoking on cTnI among
all studied patients. While Antonelli et al. [15] demonstrated
that history of smoking, age, hypertension and diabetes are
common and led to a high prevalence of cardiac co-morbidity.
AECOPD patients with a past history of LTOT, MV and
ICU admission showed a signiﬁcant statistical difference in
cTnI elevation (Table 1) these results are in agreement with
Harvey and Hancox [13], who reported that, LTOT, MV
and ICU admission reﬂect the severity of airway obstruction,
the degree of hypoxia and more burden over the right side of
the heart or progression of the disease and so more liability
to recurrent severe exacerbation.
As regards severity of exacerbation there was a signiﬁcant
statistical relationship between cTnI positivity and severity of
exacerbation, where it was +ve in 33 of 35 patients in severe
exacerbation while it was+ve only 3 of 11 in mild exacerbation
(Table 1). This is in agreement withHarvey andHancox [13] sta-
ted that serum Troponin was commonly raised in acute exac-
erbations of COPD and reﬂects the severity of exacerbations.
The severity of exacerbation reﬂects an exaggeration of the
already existing airway obstruction that constitutes a higher
load on the RT side of the heart and the associated reversible
LT ventricular dysfunction that accompany acute exacerbation
[16].
Table 3 Cardiac changes by ECG and ECHO among studied AECOPD patients and its relation to Troponin elevation.
Parameters cTnI < 0.01 (n= 18) cTnIP 0.01 (n= 42) P-value
P-pulmonale
+ve (n: 57) 15 (83.3%) 42 (100%) <0.05
ve (n: 3) 3 (16.7%) 0 (0%)
Sinus tachycardia
+ve (n: 34) 4 (22.2%) 30 (71.4%) <0.05
ve (n: 26) 14 (77.8%) 12 (28.6%)
AF
+ve (n: 4) 0 (0%) 4 (9.5%) >0.05
ve (n: 56) 18 (100%) 38 (90.5%)
Right ventricular strain
+ve (n: 53) 13 (72.2%) 40 (95.2%) <0.05
ve (n: 7) 5 (27.8%) 2 (4.8%)
Left ventricular dysfunction
+ve (n: 9) 0 (0%) 9 (21.4%) <0.05
ve (n: 51) 18 (100%) 33 (78.6%)
mPAP (mean ± SD) 27.67 ± 7.13 35.86 ± 6.3 <0.05
TR
+ve (n: 53) 12 (66.7%) 41 (97%) <0.05
ve (n: 7) 6 (33.3%) 1 (2.4%)
Table 4 Relation between Troponin level and different parameters among studied AECOPD patients.
Parameters cTnI < 0.01 (n= 18) cTnIP 0.01 (n= 42) P-value
Place admission
ICU (n: 39) 4 (22.2%) 35 (83.3%) <0.05
Ward (n: 21) 14 (77.8%) 7 (16.7%)
Need MV
Years (n: 35) 1 (25%) 34 (97.1%) <0.05
No (n: 4) 3 (75%) 1 (2.9%)
Outcome
Survival (n: 48) 18 (100%) 30 (71.4%) <0.05
Death (n: 12) 0 (%) 12 (28.6%)
Table 5 Role of Troponin value in prediction of weaning success (1st trial) vs. weaning failure in all mechanically ventilated
AECOPD patients.
Parameter Weaning Test of signiﬁcance P-value
Success (n= 23) Failure (n= 12)
Troponin Mann–Whitney test = 2.37
Median 0.08 0.2 <0.05
Range 0.0–0.32 0.03–1.3
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signiﬁcant statistical difference between cTnI positivity and
negativity in relation to the cause of exacerbation. However,
in the patient group in whom PE was the cause of exacerbation
9 patients were cTnI +ve vs. 1 patient was cTnI ve (Table 1).
This ﬁnding was in agreement with Baillard et al. [3] who re-
ported no signiﬁcant effect of infection on cTnI positivity
and they excluded patients with evidence of pulmonary embo-
lism or Q-wave myocardial infarction in their study.
In our study serum cTnI level was signiﬁcantly correlated
with theABGsparameters (PCO2, PO2andSO2), however, there
was no signiﬁcant correlation in relation to pH and HCO3 (Ta-
ble 2).These ﬁndings are in agreement with Baillard et al. [3] andMartins et al. [16] who reported that hypoxia plays a role in
cTnI release in AECOPD patients because hypoxia mediated
the contraction of small pulmonary arteries resulting in in-
creased pulmonary artery pressure and consequently cardiac
stress. This observed well in this study by occurrence of
hypoxia at the time of exacerbation associated with the eleva-
tion of mean pulmonary artery pressure which on the same
time correlated signiﬁcantly with the levels of cTnI.
As regards ECG changes (Table 3) there was a signiﬁcant
statistical difference between patients with P-pulmonale and
those without P-pulmonale (42 out of 57 patients with
P-pulmonale were +ve cTnI, while 3 out of 3 patients with-
out P-pulmonale were ve cTnI), but no signiﬁcant statisti-
Table 6 Validity of Troponin in prediction of prognosis
among all studied AECOPD patients.
Troponin cutoﬀ value Prognosis
Death (n= 12) Survival (n= 48)
>0.055 (n= 24) 9 15
60.055 (n= 36) 3 33
This table and the ROC curve show the followings:
Troponin optimal cutoff value for prediction of death >0.055 ng/
ml.
Area under the curve = 0.735, Sensitivity = 75%, Speciﬁc-
ity = 68%.Predictive value positive = 37.5%, predictive value
negative = 91.7%.P value = 0.006 with good agreement.
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ﬁbrillation (AF) this is in agreement with Baillard et al. [3]
who revealed no signiﬁcant effect of (AF) on cTnI positivity.
Sinus tachycardia showed a signiﬁcant statistical difference
between cTnI +ve and ve patients (30 out of 34 patients with
sinus tachycardia were +ve cTnI, while 4 out of 34 patients
with sinus tachycardia were ve cTnI). In agreement with
Noble et al. [7] who reported a signiﬁcant difference in cTnI
elevation between patients with tachycardia in comparison to
those without tachycardia. This may be due to pulmonary
hypertension in patients of current study with its impact upon
the right side of the heart.
Regarding Echo ﬁndings, there was a signiﬁcant statistical
difference between patients with right ventricular strain and
those without right ventricular strain, high pulmonary artery
pressure (PAP) and tricuspid valve regurge (TR) in cTnI pos-
itivity (Table 3). These ﬁndings are in agreement with ﬁndings
of Aksay et al. [17] study who revealed a signiﬁcant effect of
RV dysfunction on cTnI elevation, Harvey and Hancox [13]
who suggested that the severity of the acute exacerbation
may lead to cardiac damage and Troponin release. Potential
mechanisms of cardiac injury include: acute elevation of pul-
monary arterial pressure secondary to hypoxemic vasocon-
striction with subsequent right ventricular distension,
tachyarrhythmia, and cardiac damage mediated by sepsis
and/or metabolic stress due to hypoxia and acidosis. Seyhan
et al. [18] found a strong correlation between right ventricular
dysfunction and cTnI in a group of AECOPD patients.
Baillard et al. [3] reported neither a signiﬁcant effect of right
ventricular dysfunction upon cTnI nor did corpulmonale.
They stated that the reason for cTnI elevation is difﬁcult to
determine, because the cardiovascular alterations are complex.
During episodes of exacerbation, the increased work and oxy-
gen cost of breathing, the increase in the left ventricular after-
load related to the more negative intra thoracic pressure, the
worsening of pulmonary hypertension and the presence of
hypoxemia and hypercapnia may all contribute to the develop-
ment of cardiac injury.
In this study it was found that there was a signiﬁcant statis-
tical difference between patients with left ventricular dysfunc-
tion vs. patients without left ventricular dysfunction in cTnI
positivity and it was observed that left V dysfunction found
only in 21.4% of patients vs. right strain that was found in
95% of patient. These ﬁndings are in agreement with those
of Render et al. [5] and Connors et al. [19] who reported left
ventricular dysfunction in 30% of patients admitted for acute
exacerbation of COPD.Also MacIntyre and Huang [20] found that elevation of
Troponins (especially Troponin I) was associated with in-
creased severity of the exacerbation. However, Troponin T
and pro-brain natriuretic peptide are elevated in patients with
acute left heart failure and may be used to exclude left ventric-
ular dysfunction as the cause of AECOPD.
This study elucidated cTnI positivity was more prominent
among patients who were admitted to the ICU (83%) vs. those
managed in the ward (17%) (Table 4). ICU admission reﬂects
the severity of exacerbation, airway obstruction, hypoxemia
and hypercapnia which had been shown previously to have a
signiﬁcant effect on cTnI elevation.
Nobel et al. [7] reported that increased serum cTnI occurs
frequently in patients admitted in the ICU, during these period
patients are exposed to the insults of hypoxia, hypotension,
arrhythmia and the use of inotropic drugs that promote myo-
cardial ischemia and therefore even when intensive care had
been initiated, the processes leading to injury continued.
As regards the need for MV, cTnI positivity was more
prominent among patients who were ventilated (97%) vs.
those who did not need MV (3%) (Table 4). This is in agree-
ment with. Quenot et al. [21] and Aksay et al. [17] who men-
tioned that, there was a signiﬁcant statistical difference in
cTnI positivity between patients who needed mechanical venti-
lation and those who did not need.
Mechanical ventilation (MV) is a critical component in the
supportive care of patients with shock or respiratory failure. It
may worsen the RV function, by elevation of airway pressures
because of higher transpulmonary pressure, increase RV after-
load and increase in pleural pressure that also reduce the ve-
nous return and is transmitted to the pericardium and limits
the diastolic ﬁlling of the RV Allaqaband. [22]
In our study serum cTnI level was signiﬁcantly correlated
with the duration of hospitalization (Table 2), where cTnI pos-
itivity was more prominent in patients with longer duration.
This could be attributed to the more severity of the disease
and exacerbation (Table 1) the need for ICU and the need
for MV (Table 4).
In agreement with King et al. [23], who reported the same
ﬁnding as they found that patients with more days in the hos-
pital were more cTnI +ve than those with shorter duration.
As regards weaning success from the ﬁrst trial, there was a
signiﬁcant statistical difference in the median of cTnI between
patients who succeeded (0.08) vs. those patients who failed
(0.2). (Table 5).
As in Menzies et al. [24] and Nava et al. [25] studies on pre-
dictors of weaning failure in AECOPD patients, there were sig-
niﬁcant relations with hypercapnia, hypoxemia, FEV1 and
respiratory rate which are good predictors of elevated cTnI
which may be the hidden etiology of this ﬁnding in the current
work.
As regards survival, all dead patients were cTnI +ve
(n= 12) and neither of cTnI ve patients died (n= 18) while
30 patients with +ve cTnI survived (Table 4).Using a cutoff
value 60.055 ng/ml, cTnI has Sensitivity and Speciﬁcity of
75% and 68%, respectively, as regards survival, with a nega-
tive predictive value of 91.7% (Table 6 and Fig. 1). These ﬁnd-
ings are in agreement with Oren and Mordechai [26] who
assured the role cTnI elevation in the prediction of death. As
they found cTnI levels were signiﬁcantly higher in non-survi-
vors compared with survivors, mean cTnI was 1.35 ± 3.17
vs. 0.53 ± 2.08, respectively. In their study they showed
Figure 1 ROC curve demonstrating Speciﬁcity and Sensitivity.
Serum Troponin-I as a prognostic marker in acute exacerbated chronic obstructive pulmonary disease patients 555cTnI > 0.03 lg as the optimal cut-off level for the prediction
of mortality and revealed that the probability of survival was
signiﬁcantly lower in patients with cTnI > 0.03 lg/L.
Also Baillard et al. [3] reported the same ﬁndings in the
ICU mortality, in all hospital mortality and the positive pre-
dictive value of having a cTnI higher than 0.5 ng/ml to predict
death was 62%, and the negative predictive value was 83%.
They stated that both in-ICU and in-hospital mortality were
higher in patients with cTnI elevation at the admission.
Conclusions
Positive cTnI in AECOPD patients may suggest exacerbation
severity, pulmonary hypertension and right ventricular dys-
function. Positive cTnI is considered as a good prognostic
marker for the possibility of a need for MV and a longer dura-
tion of hospitalization. MV may further elevate cTnI in AE-
COPD patients and with a possible weaning failure.
Negative cTnI and cTnI 6 0.055 lg/L can be considered pre-
dictors of survival in AECOPD patients.
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